# Noradrenergic inhibition of definitive POMC neurons through direct and indirect mechanisms

**Authors:** Olivier Lavoie, Audrey Turmel, Axelle Khouma, Moein Minbashi Moeini, Chen Liu, Natalie J. Michael, Alexandre Caron

PMC · DOI: 10.1111/jne.70169 · 2026-03-24

## TL;DR

Norepinephrine inhibits POMC neurons in the brain through direct and indirect pathways, but this inhibition is not essential for regulating energy balance.

## Contribution

The study reveals both direct and indirect mechanisms of ADRA2A-mediated inhibition of POMC neurons and shows its limited role in energy balance regulation.

## Key findings

- Norepinephrine and UK 14,304 inhibit POMC neurons via ADRA2A-dependent potassium conductances.
- Indirect mechanisms also contribute to the inhibition, as synaptic transmission affects the response.
- Deleting Adra2a in POMC neurons modestly impairs glucose tolerance in males but has minimal impact on energy balance.

## Abstract

Norepinephrine is a key neuromodulator of hypothalamic circuits that regulate energy balance. Previous studies suggested that norepinephrine inhibits proopiomelanocortin (POMC) neurons of the arcuate nucleus via α2a‐adrenoceptors (ADRA2A), but the underlying mechanisms and physiological relevance of this pathway were not assessed. We therefore investigated how ADRA2 activation regulates POMC neuron activity and whether Adra2a expressed in POMC neurons contributes to energy and glucose homeostasis in vivo. We used whole‐cell patch clamp electrophysiology in male and female mice to evaluate the impact of norepinephrine and the ADRA2 agonist UK 14,304 on definitive POMC neurons in the arcuate nucleus. We also generated and validated a novel Adra2a‐flox mouse line, which was crossed with Pomc‐CreERT2 mice to produce inducible POMC‐specific Adra2a knockout mice (POMCKOA2A). These mice were used for both electrophysiological analyses and in vivo assessment of energy and glucose homeostasis. Multiplex RNAscope confirmed that Adra2a was highly expressed in ~50% of POMC neurons, with significantly higher expression in females. Norepinephrine and the selective ADRA2 agonist UK 14,304 robustly inhibited POMC neurons in hypothalamic slices, producing hyperpolarization, reduced firing, and decreased input resistance independent of sex. These effects were mediated in part by activation of multiple potassium conductances, as blockade of Kir and KATP channels attenuated the response. They were also partly indirect, as blockade of synaptic transmission reduced the proportion of neurons that were inhibited. Deletion of Adra2a in definitive POMC neurons had little effect on body weight, food intake, or adiposity, but modestly impaired glucose tolerance in males. Electrophysiological studies revealed that loss of Adra2a in POMC neurons prevented UK 14,304‐induced inhibition in approximately half of POMC neurons, supporting the involvement of both direct and indirect effects of UK 14,304 on POMC neuron activity. In conclusion, ADRA2A robustly inhibits hypothalamic POMC neurons through both direct and indirect mechanisms. However, Adra2a expression in POMC neurons is largely dispensable for the regulation of energy balance. These findings suggest that noradrenergic inhibition of POMC neuron activity involves additional cellular targets or network‐level pathways beyond POMC neurons themselves.

Norepinephrine and the α2‐adrenoceptor agonist UK 14,304 robustly inhibit definitive arcuate POMC neurons. Direct inhibition is mediated by ADRA2A‐dependent activation of potassium conductances, while additional indirect mechanisms also contribute. In vivo, inducible POMC‐specific Adra2a deletion minimally affects energy balance and modestly impairs glucose tolerance in males.

## Linked entities

- **Genes:** ADRA2A (adrenoceptor alpha 2A) [NCBI Gene 150], POMC (proopiomelanocortin) [NCBI Gene 5443]
- **Proteins:** ADRA2A (adrenoceptor alpha 2A), GEM (GTP binding protein overexpressed in skeletal muscle)
- **Chemicals:** norepinephrine (PubChem CID 951), UK 14,304 (PubChem CID 2435)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Pomc (pro-opiomelanocortin-alpha) [NCBI Gene 18976] {aka ACTH, BE, Beta-LPH, Clip, Gamma-LPH, Npp}, NPY (neuropeptide Y) [NCBI Gene 4852] {aka PYY4}, Esr1 (estrogen receptor 1 (alpha)) [NCBI Gene 13982] {aka ER, ER-alpha, ERa, ERalpha, ESR, Estr}, Adra1a (adrenergic receptor, alpha 1a) [NCBI Gene 11549] {aka Adra1c}, AGRP (agouti related neuropeptide) [NCBI Gene 181] {aka AGRT, ART, ASIP2}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, Adra2a (adrenergic receptor, alpha 2a) [NCBI Gene 11551] {aka Adra-2, Adra-2a, alpha(2A)AR, alpha2-C10, alpha2A, alpha2A-AR}, MC4R (melanocortin 4 receptor) [NCBI Gene 4160] {aka BMIQ20}, Cck (cholecystokinin) [NCBI Gene 12424], Gpbar1 (G protein-coupled bile acid receptor 1) [NCBI Gene 227289] {aka BG37, GPCR, GPR131, M-BAR, TGR5}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** type 2 diabetes (MESH:D003924), Obesity (MESH:D009765), glucose tolerance (MESH:D018149), cardiovascular disease (MESH:D002318), weight gain (MESH:D015430), weight loss (MESH:D015431), cancers (MESH:D009369), adiposity (MESH:D018205)
- **Chemicals:** tartrate (MESH:C029768), EGTA (MESH:D004533), MgSO4 (MESH:D008278), TTX (MESH:D013779), , UK 14,304 (MESH:D000068438), AMP1 (-), agarose (MESH:D012685), ethanol (MESH:D000431), chloride (MESH:D002712), CNQX (MESH:D018750), KCl (MESH:D011189), sodium citrate (MESH:D000077559), paraformaldehyde (MESH:C003043), sodium phosphate (MESH:C018279), 4',6- diamidino-2-phenylindole (MESH:C007293), MgCl2 (MESH:D015636), NE (MESH:D009356), K (MESH:D011188), CaCl2 (MESH:D002122), glycerol (MESH:D005990), AMP3 (MESH:C003423), BRL 44408 (MESH:C072125), Norepinephrine (MESH:D009638), HEPES (MESH:D006531), fat (MESH:D005223), tolbutamide (MESH:D014044), serotonin (MESH:D012701), BaCl2 (MESH:C024986), isoflurane (MESH:D007530), ethylene glycol (MESH:D019855), gluconate (MESH:C030691), H2O2 (MESH:D006861), corn oil (MESH:D003314), blood glucose (MESH:D001786), SI (MESH:D012825), sucrose (MESH:D013395), NaHCO3 (MESH:D017693), KOH (MESH:C029943), Tamoxifen (MESH:D013629), ATP (MESH:D000255), water (MESH:D014867), dopamine (MESH:D004298), picrotoxin (MESH:D010852), D-glucose (MESH:D005947), NaCl (MESH:D012965)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** T1020S
- **Cell lines:** RCL-tdT — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_XB27), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), HybEz  II — Mus musculus (Mouse), Hybridoma (CVCL_B3SP)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13014027/full.md

---
Source: https://tomesphere.com/paper/PMC13014027